You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for Patent: 8,961,412

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,961,412 protect, and when does it expire?

Patent 8,961,412 protects ABILIFY MYCITE KIT and is included in one NDA.

This patent has seven patent family members in six countries.

Summary for Patent: 8,961,412

Title:	In-body device with virtual dipole signal amplification
Abstract:	Virtual dipole signal amplification for in-body devices, such as implantable and ingestible devices, is provided. Aspects of the in-body deployable antennas of the invention include antennas configured to go from a first configuration to a second configuration following placement in a living body, e.g., via ingestion or implantation. Embodiments of the in-body devices are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the devices of the invention.
Inventor(s):	Hafezi; Hooman (Redwood City, CA), Costello; Benedict James (Berkeley, CA), Robertson; Timothy L. (Belmont, CA), Casillas Holen; Maria (Santa Clara, CA)
Assignee:	Proteus Digital Health, Inc. (Redwood City, CA)
Application Number:	12/238,345
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 8,961,412

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-001	Nov 13, 2017		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-003	Nov 13, 2017		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-004	Nov 13, 2017		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-005	Nov 13, 2017		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-006	Nov 13, 2017		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,961,412

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Denmark	2192946	⤷ Sign Up
European Patent Office	2192946	⤷ Sign Up
European Patent Office	4011289	⤷ Sign Up
Spain	2928197	⤷ Sign Up
Finland	2192946	⤷ Sign Up
Portugal	2192946	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2009042812	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.